Compare AstraZeneca plc (AZN) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs T Rowe Price Group Inc — how do they compare? AstraZeneca plc trades at $158.54 (market cap $248.14B), while T Rowe Price Group Inc trades at $111.17 (market cap $24.26B). The key difference: AstraZeneca plc is far larger — about 10.2× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.57%). Which is the better fit depends on your goals.
| AZN | TROW | |
|---|---|---|
Market Cap | $248.14B | $24.26B |
Sector | Health | Financials |
52-Week High | $209.48 | $121.68 |
52-Week Low | $147.06 | $86.19 |
Enterprise Value | $275.41B | $21.46B |
Dividend Yield | 2.01% | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
T. Rowe Price (TROW) trades at $111.17, down 2.29% on the day, with a bearish technical signal driven by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $2.57, supported by record assets under management. Revenue and net income have shown steady growth, with 2025 revenue at $7.31B and net income at $2.09B. The company maintains strong profitability, with a net margin of 29.26% and ROE of 20.1%. Valuation ratios appear reasonable, with a P/E of 11.42 and EV/EBITDA of 6.75. Dividends remain consistent, with a recent quarterly payment of $1.30 declared.
The outlook for TROW is mixed; fundamental strength from earnings growth and solid cash flow supports potential upside, but technical bearishness and analyst caution pose near-term risks. Investment opportunity lies in its undervalued metrics and dividend reliability, while risks include expense pressures and market volatility affecting asset flows. The consensus price target of $112.17 suggests limited upside from current levels, emphasizing a hold stance amid balanced factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
